The maximum dose is 320 mg daily. Maximum blood pressure reduction occurs within 4 weeks. For congestive heart failure, the usual dose is 40 mg twice daily. The doses may be increased to 80-160 mg twice daily.
OIG will be responsive to the needs of the TDCJ, the TBCJ, governmental agencies, and the people of Texas, by demonstrating a willingness and ability to impartially investigate administrative and criminal complaints, while protecting the rights of all concerned.
Pertuzumab (also called 2C4, trade name Perjeta) is a monoclonal antibody marketed by Genentech for the treatment of HER2 -positive breast cancer, in combination with trastuzumab and docetaxel.The first of its class in a line of agents called HER dimerization inhibitors.y binding to HER2, it inhibits the dimerization of HER2 with other HER receptors, which is hypothesized to result in slowed tumor growth. Pertuzumab received US FDA approval for the treatment of HER2-positive metastatic breast cancer on June 8, 2012.